Legal Representation
Attorney
Susan Neuberger Weller
USPTO Deadlines
Next Deadline
426 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-09-08)
Due Date
September 08, 2026
Grace Period Ends
March 08, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 20, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jul 20, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 20, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Sep 8, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 23, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 23, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Jun 3, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 21, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 12, 2020 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Aug 21, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Aug 8, 2019 | ALIE | A | ASSIGNED TO LIE |
| Jan 7, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Jan 7, 2019 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Jan 7, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Dec 14, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Dec 13, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Dec 13, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 13, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 13, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Aug 13, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 4, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 23, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Apr 19, 2018 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)
First Use Anywhere:
Jun 1, 2014
First Use in Commerce:
Jun 1, 2014
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"